Vericel (FRA:ATQP) Net Interest Margin (Bank Only) %


FRA:ATQP Vericel Corp FRA:ATQP
74 GF Score
Price €41.00
GF Value €47.68
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:ATQP
74GF Score
Vericel Corp FRA:ATQP
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €41.00 is trading 14% below its estimated GF Value™ of €47.68. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for FRA:ATQP:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €47.68 vs. price of €41.00 (14% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
74GF Score

Get the complete analysis for FRA:ATQP

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.00
Price
€47.68
GF Value